Trials / Completed
CompletedNCT02445053
Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 75 (actual)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- Not accepted
Summary
To describe the effectiveness of Kalydeco® treatment in patients with cystic fibrosis (CF) who have 1 of 8 non G551D gating CFTR mutations (G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, or G1349D).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ivacaftor |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2020-10-01
- Completion
- 2020-10-01
- First posted
- 2015-05-15
- Last updated
- 2020-11-13
Locations
15 sites across 3 countries: Italy, Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT02445053. Inclusion in this directory is not an endorsement.